TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Wielinga PY, Lwenstein C, Muff S, Munz M, Woods SC, Lutz TA
Chen Z, Mo M, Fu F, Shang L, Wang H, Liu C, Zhao Y
They swabbed the skin of 10 people before and after being injected with Vitamin B12
Arquivos brasileiros de endocrinologia e metabologia
At this time, there is no evidence linking GLP-1 medications to permanent hair loss , but temporary shedding is a well-documented phenomenonespecially among those losing weight quickly or restricting food intake
